Australian Life Sciences Stock News

PRL Global entered this result with the stock at A$1.42 and a strong short-term run, yet the headline today is not the share price. It is the squeeze on profitability. Full-year revenue sits above A$2.2b, but net profit margin over the last year is only 0.6% and edging lower compared with 0.7% a year earlier. The market is reacting to a low-margin story sitting on top of a high dividend yield of 6.34% that is not well covered by earnings or free cash flow. Is PRL Global a genuine value...

Northern Star Resources reported full-year 2026 results showing sales of A$7,623.10 million and net income of A$1,664.30 million, declared a fully franked A$0.30 per share dividend for the six months to June 30, 2026, and previously issued production guidance of approximately 350 koz gold sold for the September 2026 quarter and 1,500–1,650 koz for fiscal 2027. This combination of higher sales and earnings, fresh production guidance, and a fully franked dividend gives investors clearer...

Endeavour Group (ASX:EDV) is back in focus after reporting full year net income of A$52 million, down sharply from A$426 million a year earlier, alongside a reduced fully franked dividend. Endeavour Group’s A$3.11 share price reflects a market that has been adjusting to weaker earnings, a reduced dividend and recent CFO transition news, with the stock down over the year to date and over the past year on a total shareholder return basis despite a positive 90 day share price return. Compare...

It looks like Yancoal Australia Ltd ( ASX:YAL ) is about to go ex-dividend in the next three days. Typically, the...

Resolute Mining Limited recently reported half-year results for the period ended June 30, 2026, with net income rising to US$128.2 million and basic earnings per share from continuing operations increasing to US$0.0594, while also reaffirming 2026 production guidance toward the lower end of its 250 koz to 275 koz range and maintaining Group AISC guidance of US$2,000/oz to US$2,200/oz, subject to shifts in gold prices and fuel costs. The combination of significantly higher profitability and...

Shriro Holdings Limited ( ASX:SHM ) is about to trade ex-dividend in the next 3 days. The ex-dividend date is two...

Bathurst Resources Limited ( ASX:BRL ) investors will be delighted, with the company turning in some strong numbers...

Last week saw the newest full-year earnings release from Sports Entertainment Group Limited ( ASX:SEG ), an important...

The latest analyst coverage could presage a bad day for Rubicon Water Limited ( ASX:RWL ), with the covering analyst...

Shareholders might have noticed that Macquarie Technology Group Limited ( ASX:MAQ ) filed its yearly result this time...

Shareholders might have noticed that Kelsian Group Limited ( ASX:KLS ) filed its full-year result this time last week...

Paragon Care Limited ( ASX:PGC ) came out with its full-year results last week, and we wanted to see how the business...

Vault Minerals Limited recently reported full-year results for the 12 months to June 30, 2026, with sales of A$1,926.61 million and net income of A$278.41 million, both higher than the prior year. Basic earnings per share from continuing operations rose to A$0.267, underscoring improved profitability and operational efficiency across the business. We’ll now look at how this earnings growth, particularly the rise in net income, shapes Vault Minerals’ broader investment narrative. We've...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Clinuvel Pharmaceuticals closed at A$8.47 after a weak few months for the stock, with the share price down over the past week, month and quarter. Yet the latest full year numbers tell a calmer story. The company delivered around A$94.0m in trailing twelve month revenue with a net profit margin near 36%. That kind of profitability is unusual in biotech and underpins a trailing P/E of 12.6x that sits well below peers. For long term holders, the key point is that this remains a highly...

Insiders who purchased AU$1.36m worth of Credit Clear Limited ( ASX:CCR ) shares over the past year recouped some of...

McMillan Shakespeare stock has been grinding higher in recent months, yet the real story today is not the share price at A$20.87. The real story is a profit engine that just posted record underlying net profit after tax and amortisation of A$107.9m and a fatter 41.5% operating margin in a year that was meant to be tougher for salary packaging and fleet services. For investors, the kicker is the cash being returned. The board signed off on a fully franked full year dividend of A$1.32 per...

Global inflation readings in Europe are keeping interest rate expectations elevated, which keeps borrowing costs in focus for smaller companies. That is where the Financially Fit Penny Stocks screener becomes interesting. It filters for low priced stocks that still show solid financial health, so investors are not just chasing cheap tickers. This article highlights three stocks from the screener that may be worth considering for your watchlist. The three stocks highlighted below are just a...

Botanix Pharmaceuticals Limited ( ASX:BOT ) just released its latest yearly report and things are not looking great. It...

Emerald Resources NL ( ASX:EMR ) came out with its yearly results last week, and we wanted to see how the business is...

It looks like Monadelphous Group Limited ( ASX:MND ) is about to go ex-dividend in the next four days. The ex-dividend...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...